High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas.

BACKGROUND Aryl hydrocarbon receptor interacting protein (AIP) mutations (AIPmut) cause aggressive pituitary adenomas in young patients, usually in the setting of familial isolated pituitary adenomas. The prevalence of AIPmut among sporadic pituitary adenoma patients appears to be low; studies have not addressed prevalence in the most clinically relevant population. Hence, we undertook an international, multicenter, prospective genetic, and clinical analysis at 21 tertiary referral endocrine departments. METHODS We included 163 sporadic pituitary macroadenoma patients irrespective of clinical phenotype diagnosed at <30 years of age. RESULTS Overall, 19/163 (11.7%) patients had germline AIPmut; a further nine patients had sequence changes of uncertain significance or polymorphisms. AIPmut were identified in 8/39 (20.5%) pediatric patients. Ten AIPmut were identified in 11/83 (13.3%) sporadic somatotropinoma patients, in 7/61 (11.5%) prolactinoma patients, and in 1/16 non-functioning pituitary adenoma patients. Large genetic deletions were not seen using multiplex ligation-dependent probe amplification. Familial screening was possible in the relatives of seven patients with AIPmut and carriers were found in six of the seven families. In total, pituitary adenomas were diagnosed in 2/21 AIPmut-screened carriers; both had asymptomatic microadenomas. CONCLUSION Germline AIPmut occur in 11.7% of patients <30 years with sporadic pituitary macroadenomas and in 20.5% of pediatric patients. AIPmut mutation testing in this population should be considered in order to optimize clinical genetic investigation and management.

[1]  A. Beckers,et al.  The Epidemiology of Prolactinomas , 2017, Pituitary.

[2]  M. Junier,et al.  Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. , 2011, Endocrine-related cancer.

[3]  V. Bours,et al.  Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications , 2011, Expert review of endocrinology & metabolism.

[4]  F. Guaraldi,et al.  Familial Isolated Pituitary Adenomas: From Genetics to Therapy , 2011, Clinical and translational science.

[5]  R. Paschke,et al.  Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. , 2010, The Journal of clinical endocrinology and metabolism.

[6]  V. Bours,et al.  The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes , 2010, Clinical genetics.

[7]  J. Koivukangas,et al.  Incidence of pituitary adenomas in Northern Finland in 1992-2007. , 2010, The Journal of clinical endocrinology and metabolism.

[8]  F. Kronenberg,et al.  Lost in the space of bioinformatic tools: a constantly updated survival guide for genetic epidemiology. The GenEpi Toolbox. , 2010, Atherosclerosis.

[9]  Alberto Fernández,et al.  Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK) , 2010, Clinical endocrinology.

[10]  Fergus J Cameron,et al.  Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene. , 2009, European journal of endocrinology.

[11]  V. Esposito,et al.  Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. , 2009, Endocrine-related cancer.

[12]  A. Beckers,et al.  The epidemiology and genetics of pituitary adenomas. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[13]  Louise Izatt,et al.  Large genomic deletions in AIP in pituitary adenoma predisposition. , 2008, The Journal of clinical endocrinology and metabolism.

[14]  Jan Lubinski,et al.  Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas , 2008, Clinical endocrinology.

[15]  Julian R. E. Davis,et al.  The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. , 2008, The Journal of clinical endocrinology and metabolism.

[16]  S. Buchbinder,et al.  Aryl hydrocarbon receptor interacting protein gene (AIP) mutations are rare in patients with hormone secreting or non-secreting pituitary adenomas. , 2008, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[17]  P. Chanson,et al.  Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. , 2007, European journal of endocrinology.

[18]  S. Asa,et al.  AIP Mutations are not Identified in Patients with Sporadic Pituitary Adenomas , 2007, Endocrine pathology.

[19]  B. Estour,et al.  Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. , 2007, The Journal of clinical endocrinology and metabolism.

[20]  V. Bours,et al.  Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. , 2007, The Journal of clinical endocrinology and metabolism.

[21]  T. Sano,et al.  The aryl hydrocarbon receptor‐interacting protein gene is rarely mutated in sporadic GH‐secreting adenomas , 2007, Clinical endocrinology.

[22]  Jan Lubinski,et al.  Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations , 2007, Proceedings of the National Academy of Sciences.

[23]  L. Aaltonen,et al.  Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers , 2007, British Journal of Cancer.

[24]  L. Raffel,et al.  Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. , 2006, The Journal of clinical endocrinology and metabolism.

[25]  R. Paschke,et al.  Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene , 2006, Science.

[26]  G. Baillie,et al.  Attenuation of the Activity of the cAMP-specific Phosphodiesterase PDE4A5 by Interaction with the Immunophilin XAP2* , 2003, Journal of Biological Chemistry.

[27]  B. Scheithauer,et al.  Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. , 1987, Seminars in diagnostic pathology.

[28]  J. Urban,et al.  An evaluation of single nucleotide polymorphisms in the human aryl hydrocarbon receptor-interacting protein (AIP) gene. , 2011, Drug metabolism and pharmacokinetics.

[29]  M. Dattania,et al.  Characterization of aryl hydrocarbon receptor-interacting protein ( AIP ) mutations in familial isolated pituitary adenoma families , 2011 .

[30]  W. Ludlam.  Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline , 2011 .

[31]  M. Korbonits,et al.  AIP mutation in pituitary adenomas , 2011 .

[32]  W. Ludlam.  AIP Mutation in Pituitary Adenomas in the 18th Century and Today , 2011 .

[33]  B. Estour,et al.  Clinical characterization of familial isolated pituitary adenomas. , 2006, The Journal of clinical endocrinology and metabolism.

[34]  A. Beckers,et al.  of Liège, Belgium High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province , 2006 .